Penn affirms commitment to racial equity as Derek Chauvin trial approaches verdict thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.
E-Mail
PHILADELPHIA Researchers at Penn Medicine have identified more genetic mutations that strongly predispose younger, otherwise healthy women to peripartum cardiomyopathy (PPCM), a rare condition characterized by weakness of the heart muscle that begins sometime during the final month of pregnancy through five months after delivery. PPCM can cause severe heart failure and often leads to lifelong heart failure and even death. The study is published today in
Circulation.
PPCM affects women in one out of every 2,000 deliveries worldwide, with about a third of those women developing heart failure for life, and about five percent of them dying within a few years. Maternal mortality in the United States has doubled in the last 20 years, and PPCM is a leading cause of these deaths. Previously, the reasons behind why women developed PPCM remained a mystery until a 2016 study strongly suggested that some genetic mutations predispose women to the disease.
Read Time:
People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response. The team found that those who did not have COVID-19âcalled COVID naïveâdid not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.
A message to the Penn community on racial equity and justice upenn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upenn.edu Daily Mail and Mail on Sunday newspapers.
E-Mail
PHILADELPHIA A retrospective study led by researchers from Penn Medicine found that with MitraClip for treatment of secondary mitral regurgitation (MR), a heart disease associated with problems in the left ventricle, there was no negative effect of having a slightly smaller mitral valve opening as long as there was good reduction of the mitral regurgitation. The study is published today in
JACC: Cardiovascular Interventions. This data is very reassuring for physicians who place MitraClips in patients with secondary mitral regurgitation. It demonstrates that the benefits of MR reduction in patients with heart failure were maintained even when mild-to-moderate mitral stenosis, which can be caused by a narrowing of the mitral valve, occurred after MitraClip, said lead author Howard C. Herrmann, MD, the John Winthrop Bryfogle Professor of Cardiovascular Diseases in the Perelman School of Medicine at the University of Pennsylvania and Health System Director for Interventi